Representative photo (AP) NEW DELHI: Drug price regulator National Pharmaceuticals Pricing Authority (NPPA) has approved a 20% price hike for Serum Institute of India’s BCG, measles and measles-rubella vaccines.This move is unusual since price hikes are rare when one company dominates the market.NPPA had fixed the pr-ice ceiling in Dec 2024 based on Pharmarack data after applying monopoly reduction of 17.1% under Drugs Prices Control Order, 2013. Serum Institute filed a review application with the department of pharmaceuticals (DoP), which referred the matter to NPPA. Serum Institute had argued that the vaccines were complex, had few alternatives, and costs had been rising.”The vaccines in question are of critical public health significance, have shown relatively stable price trends, impose minimal financial burden on citizens and are supplied by a single manufacturer at relatively low prices,” read DoP’s submission to NPPA.NPPA decided that ceiling price may be revised without applying reduction under monopolistic condition “to address the grievance of the applicant as well as to ensure sufficient availability of the drug in the market”, the notification said. The BCG vaccine now costs Rs 9.9 per dose (up from Rs 8.2), measles-rubella Rs 87.93 (from Rs 72.9), and measles Rs 62 (Rs 51.4).Get the latest India news and live updates. Download the TOI App.End of ArticleFollow Us On Social MediaVideosPM Modi, Trump Hold Bilateral Talks On Hormuz, Seafarers, Defence, Trade TiesSpeaker to Hear TMC and Rebel Camps Before Deciding on Breakaway Faction’s Claim’If India Comes Under Attack And Modi Is The Leader, US Will Help’: Trump’It’s A Rough…’: Trump Reacts To Indian Seafarers’ Deaths As PM Modi Raises ConcernsAfter BJP Exit, Annamalai Eyes New Political Party With Growing Membership Base’We Are Prepared’: Akhilesh Yadav Rejects Split Buzz, Accuses BJP of Engineering Defections | WatchRevolt-Hit TMC Asked to Vacate Kolkata Headquarters Amid Lease DisputeIndia Blocks Telegram Ahead Of NEET Re-Exam, But It Remains Operational On VPNAs NEET Re-Exam Nears, Two Young Aspirants Die By Suicide In Delhi And DehradunUS Map Shows PoJK As Pakistan’s Part, Drops ‘Indo’ From Pacific Command Name123Photostories5 luxury residential regions in Greater Noida attracting premium homebuyersWhat to do when your child is angry: Parents share most effective techniques that almost invariably workedRupali Ganguly’s rise to fame: From a filmmaker’s daughter to Indian television’s leading ladyHow to recognize manipulation: 5 life skills parents must teach children6 fun, cute and unique souvenirs you must bring home from JapanYou may not notice these health problems after 40 until it’s too late: The essential tests every man needsTop 10 safest countries in the world in 2026; what travellers should know5 signs of narcissism – And 3 ways on how to deal with a narcissist, reveals pyschologist Dr Ramani DurvasulaPrincess Diana’s timeless beauty secrets that are still relevant today10 beautiful baby girl names inspired by spring flowers123Hot PicksLionel Messi WifeVaibhav SooryavanshiDehradun NEET Aspirant DieFIFA World Cup Free Live Streamingilia topuriaIND vs AFG ScorecardUGC NET admit cardNHL TradeTyson Fury vs Anthony JoshuaTop TrendingSairaj BahutaleFrance vs Senegal Live ScoreKarley SwindelFIFA World Cup 2026Jewar Noida International AirportHormuz BlockadeSpaceXCBSE 10th Second Board Result 2026Eknath ShindeAustria vs Jordan Match Result
NEW DELHI: Drug price regulator National Pharmaceuticals Pricing Authority (NPPA) has approved a 20% price hike for Serum Institute of India’s BCG, measles and measles-rubella vaccines.This move is unusual since price hikes are rare when one company dominates the market.NPPA had fixed the pr-ice ceiling in Dec 2024 based on Pharmarack data after applying monopoly reduction of 17.1% under Drugs Prices Control Order, 2013. Serum Institute filed a review application with the department of pharmaceuticals (DoP), which referred the matter to NPPA. Serum Institute had argued that the vaccines were complex, had few alternatives, and costs had been rising.“The vaccines in question are of critical public health significance, have shown relatively stable price trends, impose minimal financial burden on citizens and are supplied by a single manufacturer at relatively low prices,” read DoP’s submission to NPPA.NPPA decided that ceiling price may be revised without applying reduction under monopolistic condition “to address the grievance of the applicant as well as to ensure sufficient availability of the drug in the market”, the notification said. The BCG vaccine now costs Rs 9.9 per dose (up from Rs 8.2), measles-rubella Rs 87.93 (from Rs 72.9), and measles Rs 62 (Rs 51.4).
